Ustekinumab: when everything else fails?
- 18 March 2011
- journal article
- case report
- Published by Wiley in International Journal of Dermatology
- Vol. 50 (4) , 478-482
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Comparison of Ustekinumab and Etanercept for Moderate-to-Severe PsoriasisNew England Journal of Medicine, 2010
- Long-term efficacy of biologics in the treatment of psoriasis: what do we really know?Dermatologic Therapy, 2009
- UstekinumabDrugs, 2009
- Ustekinumab for psoriatic arthritis.The Lancet, 2009
- Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trialThe Lancet, 2009
- Ustekinumab for chronic plaque psoriasisThe Lancet, 2008
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)The Lancet, 2008
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)The Lancet, 2008
- From conventional to cutting edge: the new era of biologics in treatment of psoriasisDermatologic Therapy, 2008
- A Human Interleukin-12/23 Monoclonal Antibody for the Treatment of PsoriasisNew England Journal of Medicine, 2007